BRPI0718927A2 - Método de imunização contra os quatro sorotipos da dengue. - Google Patents

Método de imunização contra os quatro sorotipos da dengue.

Info

Publication number
BRPI0718927A2
BRPI0718927A2 BRPI0718927-3A2A BRPI0718927A BRPI0718927A2 BR PI0718927 A2 BRPI0718927 A2 BR PI0718927A2 BR PI0718927 A BRPI0718927 A BR PI0718927A BR PI0718927 A2 BRPI0718927 A2 BR PI0718927A2
Authority
BR
Brazil
Prior art keywords
serotipes
immunization method
method against
against dengue
dengue
Prior art date
Application number
BRPI0718927-3A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of BRPI0718927A2 publication Critical patent/BRPI0718927A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0718927-3A2A 2006-12-01 2007-11-30 Método de imunização contra os quatro sorotipos da dengue. BRPI0718927A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue
PCT/FR2007/052431 WO2008065315A1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (1)

Publication Number Publication Date
BRPI0718927A2 true BRPI0718927A2 (pt) 2014-04-08

Family

ID=38198298

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0718927-3A2A BRPI0718927A2 (pt) 2006-12-01 2007-11-30 Método de imunização contra os quatro sorotipos da dengue.

Country Status (16)

Country Link
US (2) US7718359B2 (enExample)
EP (1) EP2099483B1 (enExample)
JP (1) JP5269803B2 (enExample)
KR (1) KR20090087890A (enExample)
CN (1) CN101541344A (enExample)
AR (1) AR064009A1 (enExample)
AU (1) AU2007327367B2 (enExample)
BR (1) BRPI0718927A2 (enExample)
CA (1) CA2668570A1 (enExample)
FR (1) FR2909286B1 (enExample)
IL (2) IL198466A (enExample)
MX (1) MX2009004223A (enExample)
MY (1) MY180698A (enExample)
TW (1) TWI400249B (enExample)
WO (1) WO2008065315A1 (enExample)
ZA (1) ZA200902540B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
US9211323B2 (en) * 2009-06-01 2015-12-15 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
WO2011026139A1 (en) * 2009-08-31 2011-03-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
MY168959A (en) 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
CA2878599A1 (en) 2012-07-24 2014-01-30 Jiansheng Yao Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
MX366154B (es) * 2013-06-21 2019-06-28 Merck Sharp & Dohme Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
KR20230154072A (ko) 2014-09-26 2023-11-07 세퀴러스 유케이 리미티드 면역손상된 대상체의 백신 접종
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
AU2018346724B2 (en) 2017-10-05 2025-01-09 Sanofi Pasteur Compositions for booster vaccination against dengue
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用
MX2022001742A (es) 2019-08-16 2022-04-07 Takeda Vaccines Inc Metodos para prevenir el dengue y la hepatitis a.
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
KR20230147098A (ko) * 2021-01-28 2023-10-20 백신벤트 게엠베하 B 세포 매개 면역 반응을 조절하기 위한 방법 및 수단(method and means for modulating b-cell mediated immune responses)
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2023158989A1 (en) 2022-02-15 2023-08-24 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
EP4519847A1 (en) 2022-05-04 2025-03-12 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
CN120225693A (zh) 2022-11-18 2025-06-27 武田疫苗股份有限公司 测定制剂中具有包含至少一个减毒基因座的核苷酸序列的活减毒黄病毒的比例的方法
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061916A1 (en) 1998-05-29 1999-12-02 Epimmune, Inc. Identification of broadly reactive dr restricted epitopes
US6537557B1 (en) 1999-03-26 2003-03-25 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-4 virus vaccine
AU779280B2 (en) 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CA2941182A1 (en) * 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
PT1159968E (pt) * 2000-05-30 2008-11-20 Univ Mahidol Estirpes atenuadas de vírus do dengue e a sua utilização numa composição de vacina
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
BRPI0408774A (pt) 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
WO2006134433A1 (en) * 2005-06-17 2006-12-21 Sanofi Pasteur Dengue serotype 1 attenuated strain
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.

Also Published As

Publication number Publication date
MX2009004223A (es) 2009-04-30
US20080131460A1 (en) 2008-06-05
IL198466A (en) 2014-01-30
MY180698A (en) 2020-12-07
US20100239612A1 (en) 2010-09-23
AR064009A1 (es) 2009-03-04
KR20090087890A (ko) 2009-08-18
CA2668570A1 (en) 2008-06-05
TW200829599A (en) 2008-07-16
TWI400249B (zh) 2013-07-01
WO2008065315A1 (fr) 2008-06-05
JP5269803B2 (ja) 2013-08-21
IL230052A0 (en) 2014-01-30
IL198466A0 (en) 2011-08-01
AU2007327367B2 (en) 2013-05-09
ZA200902540B (en) 2010-07-28
JP2010511022A (ja) 2010-04-08
FR2909286A1 (fr) 2008-06-06
US7718359B2 (en) 2010-05-18
CN101541344A (zh) 2009-09-23
EP2099483B1 (fr) 2013-12-25
FR2909286B1 (fr) 2012-06-08
AU2007327367A1 (en) 2008-06-05
EP2099483A1 (fr) 2009-09-16

Similar Documents

Publication Publication Date Title
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
CR20130418A (es) Anticuerpos contra la angiopoyetina 2 humana (divisional exp. 2011-0321)
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
EP1864971A4 (en) PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
BRPI0905663A2 (pt) "emulsão estável, processo de preparação da emulsão estável e uso emulsão"
BRPI0718688A2 (pt) Composições de baixa irritação e métodos para preparar as mesmas.
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
DOP2006000093A (es) Anticuerpos contra miostatina
EP1903866A4 (en) IMPROVED RELEASE OF TETRAHYDROCANNABINOL
SI1998783T1 (sl) Oftalmični sestavki, ki obsegajo providon-jod
BRPI0814941A2 (pt) Composição de tratamentode semente, e, método de tratamento de semente.
IL196331A0 (en) Method of immunization against the four serotypes of dengue
IL198466A0 (en) Immunization protocol against the 4 dengue serotypes
NL2000690A1 (nl) Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine.
MX277615B (es) Metodo para preparar polisacarido microfibrilar.
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
FR2898636B1 (fr) Structure de queue-d'aronde de soufflante.
NL1033746A1 (nl) Rotorsproeier.
NL1032915A1 (nl) Katheterpunt.
CL2007002727A1 (es) Proceso de preparacion de anastrozol; y compuestos intermediarios.
EP2039342A4 (en) MEANS FOR MAINTAINING THE HARDENING TISSUE STRUCTURE
ITBO20060029U1 (it) Attacco per cerniera.
FR2927632B1 (fr) Cornee et muqueuse reconstruites.
FR2896246B1 (fr) Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
ITPD20080020A1 (it) Procedimento per l' ottenimento di manufatti di copolimero stirene - etilene - butadiene - stirene e copolimero stirene - etilene - propilene - stirene.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]